All In Biotech

NDA 020356 · Azurity

Sular

Nisoldipine · Oral · Dihydropyridine Calcium Channel Blocker

Novel

Last checked: Nov 19, 2026Latest source record: Jun 13, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Feb 2, 1995

Approved uses

1

Original approval plus efficacy supplements

Registered trials

5

0 Phase 3, 0 recruiting

FAERS reports

1,198

780 serious, 123 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 12, 2026.

INDICATIONS AND USAGE SULAR is indicated for the treatment of hypertension. It may be used alone or in combination with other anti-hypertensive agents.

Mechanism: Mechanism of Action Nisoldipine is a member of the dihydropyridine class of calcium channel antagonists (calcium ion antagonists or slow channel blockers) that inhibit the transmembrane influx of calcium into vascular smooth muscle and cardiac muscle. It reversibly competes with other dihydropyridines for binding to the calcium channel. Because the contractile process of vascular smooth muscle is dependent upon the movement of extracellular calcium into the muscle through specific ion channels, inhibition of the calcium channel results in dilation of the arterioles. In vitro studies show that...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 2, 1995 Original approval · Type 1 - New Molecular Entity LetterReview
8 products under this application
  • SULAR · NISOLDIPINE 25.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
  • SULAR · NISOLDIPINE 40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
  • SULAR · NISOLDIPINE 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
  • SULAR · NISOLDIPINE 17MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB
  • SULAR · NISOLDIPINE 34MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB
  • SULAR · NISOLDIPINE 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
  • SULAR · NISOLDIPINE 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
  • SULAR · NISOLDIPINE 8.5MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Nisoldipine" as an intervention, any sponsor and status, largest first.

All 5 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea89
  • drug ineffective79
  • dizziness77
  • headache76
  • fatigue74
  • renal failure65
  • pain64
  • dyspnoea63
  • asthenia62
  • diarrhoea59
  • anxiety54
  • myocardial infarction54

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200458
200549
200682
200770
200881
2009106
2010111
201183
201285
201340
201454
201555
201651
201745
201858
201965
202028
202121
202215
20239
202415
202510
20267

Recalls

1 FDA enforcement reports for this application.

  • Jul 24, 2015 · Class III · Terminated

    Failed Dissolution Specifications

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sular (Nisoldipine)

2024 spending

$319K

Beneficiaries

26

126 claims

Per beneficiary

$12,271

$30.25 per unit

View as table
YearSpending
2020$602,980
2021$517,711
2022$473,530
2023$351,576
2024$319,058

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 177 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.